Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

NCT01131234 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

NIH

Sponsor class

Conditions

Adult Anaplastic Astrocytoma
Adult Anaplastic Ependymoma
Adult Anaplastic Oligodendroglioma
Adult Brain Stem Glioma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Adult Mixed Glioma
Adult Solid Neoplasm
Male Breast Carcinoma
Recurrent Adult Brain Neoplasm
Recurrent Breast Carcinoma
Recurrent Colon Carcinoma
Recurrent Melanoma
Recurrent Non-Small Cell Lung Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Ovarian Germ Cell Tumor
Recurrent Pancreatic Carcinoma
Recurrent Rectal Carcinoma
Recurrent Renal Cell Carcinoma
Stage III Pancreatic Cancer
Stage III Renal Cell Cancer
Stage IIIA Colon Cancer
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIA Ovarian Cancer
Stage IIIA Ovarian Germ Cell Tumor
Stage IIIA Rectal Cancer
Stage IIIA Skin Melanoma
Stage IIIB Breast Cancer
Stage IIIB Colon Cancer
Stage IIIB Non-Small Cell Lung Cancer
Stage IIIB Ovarian Cancer
Stage IIIB Ovarian Germ Cell Tumor
Stage IIIB Rectal Cancer
Stage IIIB Skin Melanoma
Stage IIIC Breast Cancer
Stage IIIC Colon Cancer
Stage IIIC Ovarian Cancer
Stage IIIC Ovarian Germ Cell Tumor
Stage IIIC Rectal Cancer
Stage IIIC Skin Melanoma
Stage IV Breast Cancer
Stage IV Non-Small Cell Lung Cancer
Stage IV Ovarian Cancer
Stage IV Ovarian Germ Cell Tumor
Stage IV Pancreatic Cancer
Stage IV Renal Cell Cancer
Stage IV Skin Melanoma
Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer

Interventions

DRUG: Gamma-Secretase Inhibitor RO4929097
DRUG: Cediranib Maleate
OTHER: Pharmacological Study
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)